Ketanserin	ketanserin	O	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
reverses	reverses	O	O	O	O
alfentanil-induced	alfentanil-induced	O	O	O	O
muscle	muscle	O	DISEASE	OTHERS	I
rigidity	rigidity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Systemic	systemic	O	O	O	O
pretreatment	pretreatment	O	O	O	O
with	with	O	O	O	O
ketanserin	ketanserin	O	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
relatively	relatively	O	O	O	O
specific	specific	O	O	O	O
type-2	type-2	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
,	,	O	O	O	O
significantly	significantly	O	O	O	O
attenuated	attenuated	O	O	O	O
the	the	O	O	O	O
muscle	muscle	O	DISEASE	OTHERS	I
rigidity	rigidity	O	DISEASE	OTHERS	I
produced	produced	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
potent	potent	O	O	O	O
short-acting	short-acting	O	O	O	O
opiate	opiate	O	O	O	O
agonist	agonist	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Following	following	O	O	O	O
placement	placement	O	O	O	O
of	of	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
electrodes	electrodes	O	O	O	O
in	in	O	O	O	O
each	each	O	O	O	O
animal	animal	O	O	O	O
's	's	O	O	O	O
left	left	O	O	O	O
gastrocnemius	gastrocnemius	O	O	O	O
muscle	muscle	O	O	O	O
,	,	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
assessed	assessed	O	O	O	O
by	by	O	O	O	O
analyzing	analyzing	O	O	O	O
root-mean-square	root-mean-square	O	O	O	O
electromyographic	electromyographic	O	O	O	O
activity	activity	O	O	O	O
.	.	O	O	O	O

Intraperitoneal	intraperitoneal	O	O	O	O
ketanserin	ketanserin	O	O	OTHERS	I
administration	administration	O	O	O	O
at	at	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
0.63	0.63	O	O	O	O
and	and	O	O	O	O
2.5	2.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
prevented	prevented	O	O	O	O
the	the	O	O	O	O
alfentanil-induced	alfentanil-induced	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
electromyographic	electromyographic	O	O	O	O
activity	activity	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
animals	animals	O	O	O	O
pretreated	pretreated	O	O	O	O
with	with	O	O	O	O
saline	saline	O	O	O	O
.	.	O	O	O	O

Chlordiazepoxide	chlordiazepoxide	O	O	OTHERS	I
at	at	O	O	O	O
doses	doses	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
10	10	O	O	O	O
mg/kg	mg/kg	O	O	O	O
failed	failed	O	O	O	O
to	to	O	O	O	O
significantly	significantly	O	O	O	O
influence	influence	O	O	O	O
the	the	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
produced	produced	O	O	O	O
by	by	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Despite	despite	O	O	O	O
the	the	O	O	O	O
absence	absence	O	O	O	O
of	of	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
animals	animals	O	O	O	O
that	that	O	O	O	O
received	received	O	O	O	O
ketanserin	ketanserin	O	O	OTHERS	I
(	(	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
0.31	0.31	O	O	O	O
mg/kg	mg/kg	O	O	O	O
i.p	i.p	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
motionless	motionless	O	O	O	O
,	,	O	O	O	O
flaccid	flaccid	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
less	less	O	O	O	O
responsive	responsive	O	O	O	O
to	to	O	O	O	O
external	external	O	O	O	O
stimuli	stimuli	O	O	O	O
than	than	O	O	O	O
were	were	O	O	O	O
animals	animals	O	O	O	O
receiving	receiving	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
.	.	O	O	O	O

Rats	rats	O	O	O	O
that	that	O	O	O	O
received	received	O	O	O	O
ketanserin	ketanserin	O	O	OTHERS	I
and	and	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
exhibited	exhibited	O	O	O	O
less	less	O	O	O	O
rearing	rearing	O	O	O	O
and	and	O	O	O	O
exploratory	exploratory	O	O	O	O
behavior	behavior	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
end	end	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
60-min	60-min	O	O	O	O
recording	recording	O	O	O	O
period	period	O	O	O	O
than	than	O	O	O	O
did	did	O	O	O	O
animals	animals	O	O	O	O
that	that	O	O	O	O
received	received	O	O	O	O
ketanserin	ketanserin	O	O	OTHERS	I
alone	alone	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
previous	previous	O	O	O	O
work	work	O	O	O	O
,	,	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
muscle	muscle	O	DISEASE	OTHERS	I
rigidity	rigidity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
clinically	clinically	O	O	O	O
relevant	relevant	O	O	O	O
side-effect	side-effect	O	O	O	O
of	of	O	O	O	O
parenteral	parenteral	O	O	O	O
narcotic	narcotic	O	O	O	O
administration	administration	O	O	O	O
,	,	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
partly	partly	O	O	O	O
mediated	mediated	O	O	O	O
via	via	O	O	O	O
serotonergic	serotonergic	O	O	O	O
pathways	pathways	O	O	O	O
.	.	O	O	O	O

Pretreatment	pretreatment	O	O	O	O
with	with	O	O	O	O
type-2	type-2	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
antagonists	antagonists	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
be	be	O	O	O	O
clinically	clinically	O	O	O	O
useful	useful	O	O	O	O
in	in	O	O	O	O
attenuating	attenuating	O	O	O	O
opiate-induced	opiate-induced	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
further	further	O	O	O	O
studies	studies	O	O	O	O
will	will	O	O	O	O
be	be	O	O	O	O
necessary	necessary	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
interaction	interaction	O	O	O	O
of	of	O	O	O	O
possibly	possibly	O	O	O	O
enhanced	enhanced	O	O	O	O
CNS	cns	O	O	O	O
,	,	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
respiratory	respiratory	O	DISEASE	OTHERS	I
depression	depression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

